Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.490
-0.010 (-0.40%)
At close: Aug 26, 2026, 4:00 PM EDT
2.484
-0.006 (-0.23%)
After-hours: Aug 26, 2026, 7:30 PM EDT
Inhibikase Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
453.37M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 260.50K | 137.06K | 111.03% |
| Dec 31, 2022 | 123.44K | -2.98M | -96.02% |
| Dec 31, 2021 | 3.10M | 2.40M | 343.92% |
| Dec 31, 2020 | 698.47K | -424.27K | -37.79% |
| Dec 31, 2019 | 1.12M | -2.92M | -72.22% |
| Dec 31, 2018 | 4.04M | 1.98M | 96.07% |
| Dec 31, 2017 | 2.06M | 1.09M | 113.04% |
| Dec 31, 2016 | 967.39K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| Prothena Corporation | 54.53M |
| Arcturus Therapeutics Holdings | 29.37M |
| Capricor Therapeutics | 11.13M |
| Ocugen | 4.58M |
| EyePoint | 2.79M |
| Compass Therapeutics | 850.00K |
IKT News
- 15 days ago - Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c) - TheFly
- 15 days ago - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 15 days ago - Inhibikase Therapeutics Earnings release: Q2 2026 - Filings
- 15 days ago - Inhibikase Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA - TheFly
- 4 weeks ago - Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - GlobeNewsWire
- 5 weeks ago - Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation - TheFly
- 6 weeks ago - Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - GlobeNewsWire